Royalty Report: Diagnostic, Imaging, Drugs – Collection: 237237


Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 5


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 5

Primary Industries

  • Diagnostic
  • Imaging
  • Drugs
  • Scientific & Technical Instruments
  • Device
  • Medical
  • Disease
  • cardiac

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 237237

License Grant
Licensor, an individual, grants a nonexclusive, license, without the right to sublicense, under the Patent to make, have made, use, offer to Sell, Sell, import, export and otherwise transfer the MR Contrast Agent Product during the term of this Agreement.

With this Agreement, Licensor discharges, releases, promises and covenants not to sue, threaten to sue or otherwise disturb Licensee, and its Affiliates, and any Licensees Licensee, subcontractor, supplier, distributor, vendor, reseller, purchaser, or user of the MR Contrast Agent Product, acquired directly or indirectly from Licensee {or its Affiliates) or a Licensees Licensee in any country in the world, for any claim or cause of action based upon the Licensor MR Intellectual Property and the manufacture, use, Sale, advertisement, offer for Sale, importation, lease, or otherwise transfer or disposition of the MR Contrast Agent Product, whether such claim or cause of action is presently known or unknown.

License Property
MR ContrastAgent(s) means any contrast agent used in, or capable of use in CEMRA procedures.  CE-MRA means contrast-enhanced MR angiography.  MR means magnetic resonance imaging and magnetic resonance angiography.

Licensor is recognized for his expertise in clinical magnetic resonance imaging and magnetic resonance angiography and as the inventor of contrast-enhanced magnetic resonance angiography techniques.

MR Imaging System{s) means any magnetic resonance transmission/receiving system, inclusive of all hardware (for example, without limitation, imaging coils) and software components, that is capable of performing CE-MRA procedures.

IP relates to the magnetic resonance imaging drug, MS-325.

MS-325 is designed to provide visual imaging of the vascular system, through a type of MRI known as magnetic resonance angiography, or MRA.

Field of Use
The use of this agreement is to develop and commercialize contrast agents used in magnetic resonance imaging and magnetic resonance angiography.

MS-325 is specifically designed to enhance the quality of magnetic resonance images of the arteries and veins and to provide physicians with a superior method for diagnosing vascular disease.

IPSCIO Record ID: 133546

License Grant
Licensor and German Licensee wish to establish a collaborative alliance to complete the development of Compound MS-325, and to market and sell Licensed Products in the Territory.

Licensor grants the German Licensee the exclusive right and license under the Patent Rights, Technology, Joint Patent Rights and Joint Program Technology to develop, use, offer for sale, sell, have sold, import and have imported Licensed Products in the Territory for use in the Field, and to manufacture or have manufactured Compound MS-325 and Licensed Products (to the extent manufacture of Compound MS-325 and Licensed Products is covered by the Manufacturing Agreement, manufacture by or on behalf of Licensee, with the right to sublicense.

License Property
Licensor is developing a proprietary blood pool agent coded as MS-325 which is intended for use as an enhancer for magnetic resonance imaging, which compound is covered by said MGH patents and patent applications as well as by Licensee Patents and patent applications.

Licensed Product shall mean any product comprising Compound MS-325.

Field of Use
The field means all indications comprehended by the term Blood Pool Magnetic Resonance Contrast Agents and magnetic resonance imaging.

IPSCIO Record ID: 204334

License Grant
Licensor grants under its Patents personal, nonexclusive and nontransferable licenses for Communications Products, Healthcare Products, NMR Coil Sets and Squid Sensors.
License Property
The Type 1 Licensed Product is Communications Product means components for the transmission and reception of radio frequency signals including, but not limited to, front-end receivers and antennas.

The Type 2 Licensed Products are:
Healthcare Product means a detector for magnetic resonance imaging.

NMR Coil Set means patterned and tested radio frequency devices for use in Nuclear Magnetic Resonance (NMR) systems.

Squid Sensor means superconducting quantum interference devices (SQUIDs) for measuring magnetic properties of materials for use in the field of healthcare and for research.

Field of Use
The Squid Sensor is to be used in the field of healthcare and for research.

IPSCIO Record ID: 5486

License Grant
The Company has the exclusive worldwide rights to develop, manufacture and market a patented color magnetic resonance imaging technology.
License Property
Technology' shall mean a method for colorizing and displaying MRIs (MRI colorization technology – US Patents #5,332,968 and #5,410,2)

IPSCIO Record ID: 237373

License Grant
The parties entered into a Development and License Agreement effective March 29, 1996 and amended as of October 4, 1999 (License Agreement), whereby Licensee licensed to Licensor rights to its proprietary compound MS-325 under the Patent Rights for the purposes of development and marketing said compound in Japan.

With this agreement,  Licensee desires to reacquire the rights previously conveyed to Licensor.

As of the Effective Date, all licenses, rights, title and interest in the Licensed Compound and Licensed Product previously conveyed to Licensor under the Patent Rights pursuant to the License Agreement are terminated and shall revert to Licensee, and Licensor shall cease all activity under the Development Program.

As of the Effective Date, Licensor shall terminate all sublicenses and subcontracts granted under or in connection with the previous License Agreement, obtain any Proprietary Materials and Confidential Information from the sublicensees and subcontractors, and convey any such Proprietary Materials and Confidential Information to Licensee.

License Property
Licensed Compound shall mean Compound MS-325.

Licensed Products shall mean any product comprising MS-325.

MS-325 is an injectable intravascular contrast agent.

Field of Use
MS-325 is designed for multiple cardiovascular imaging applications, including peripheral vascular disease and coronary artery disease.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.